Cerapedics, Inc., a Westminster, Colorado-based medical device company, has completed a $19m Series C financing.
The round was led by new investors MedImmune Ventures and CVF LLC, an affiliate of Henry Crown and Company, with participation from existing investors OrbiMed Advisors and NGN Capital.
In conjunction with the funding, Sam Wu, M.D., Ph.D., Managing Director of MedImmune Ventures, joined the company’s Board of Directors.
Led by Paul Mraz, President and Chief Executive Officer, and Andy Handwerker, Chief Operating Officer, Cerapedics recently received agreement from the U.S. Food and Drug Administration (FDA) to proceed with a PMA modular submission for its ongoing IDE clinical trial studying i-FACTOR peptide enhanced bone graft in cervical spine fusion and has commenced that process.
The company intends to use the capital to continue activities with its current Investigational Device Exemption (IDE) clinical trial in the United States studying its i-FACTOR(TM) peptide enhanced bone graft for cervical spine applications, to prepare for commercialization upon FDA approval, to accelerate the development of products and expand sales and marketing efforts for the i-FACTOR bone graft outside the United States.
FinSMEs
12/12/2012